Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma recurrence patterns after negative sentinel lymphadenectomy.

Theresa G Zogakis1, Richard Essner, He-jing Wang

  • 1Roy E. Coats Research Laboratories, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA.

Archives of Surgery (Chicago, Ill. : 1960)
|September 21, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers in Melanoma: Updates in Prognosis and Management.

Cancers·2026
Same author

Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis.

Dermatology and therapy·2026
Same author

Variation in the Surgical Care of Early Stage Melanoma Based on Surgical Subspecialty: Evaluation of Large Healthcare System.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

Male or female sex stratified by age does not impact survival in patients with metastatic melanoma receiving immunotherapy.

American journal of surgery·2025
Same author

Metastatic Melanoma Outcomes and the Evolving Role of Surgery in the Immunotherapy Era.

JAMA surgery·2025
Same author

A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP.

Cancer medicine·2025

Even with negative sentinel nodes (SNs), melanoma recurrence is possible. Distant recurrences significantly impact survival, highlighting the need for careful patient monitoring and SN analysis.

Area of Science:

  • Oncology
  • Surgical Pathology
  • Cancer Metastasis

Background:

  • Sentinel node (SN) biopsy is crucial for melanoma staging.
  • Tumor-negative SNs do not entirely rule out melanoma recurrence.
  • Understanding recurrence patterns in SN-negative patients is vital for prognosis.

Purpose of the Study:

  • To characterize patterns of melanoma recurrence in patients with tumor-negative SNs.
  • To determine the prognostic significance of recurrence sites.
  • To assess the false-negative rate of SN histopathology.

Main Methods:

  • Retrospective review of melanoma patients undergoing lymphatic mapping and sentinel lymphadenectomy (1995-2002).
  • Histopathologic reexamination of SNs from patients who developed recurrence.

Related Experiment Videos

  • Analysis of survival differences based on recurrence location and false-negative SN rates.

    • Main Results:

    • 8.9% of 773 patients with tumor-negative SNs experienced recurrence.
    • Three-year survival varied significantly by recurrence site: distant (17.1%), local/in-transit (48.7%), and regional basin (63.5%).
    • Reexamination identified a 1.7% false-negative SN rate, with some cases leading to same-basin recurrence.

    Conclusions:

    • Tumor-negative SNs are valuable prognostic indicators, with low recurrence rates (8.9%).
    • The low incidence of regional basin recurrence supports the accuracy of sentinel lymphadenectomy in detecting nodal metastasis.
    • Distant recurrence significantly portends a poorer prognosis.